



NUMICO

Press Release

Second Quarter and First Half Year Results 2006

Strong First Half Year Performance – 2006 Outlook Reconfirmed

3 August 2006

Financial Highlights First Half Year 2006 *(on a comparable basis)*¹

- Total sales up 12.4%; EBITA margin at 19.2%
- Nutricia Baby sales up 10.6%; EBITA margin at 19.7%
- Dumex sales up 25.7%; EBITA margin at 18.0%
- Nutricia Clinical sales up 10.1%; EBITA margin at 26.1%
- Normalised² profit up 37.8% and normalised basic EPS up 20.6% (at reported rates)
- Cash generated from operations at €228 mln

Financial Highlights Second Quarter 2006 *(on a comparable basis)*¹

- Total sales up 11.3%; EBITA margin at 19.3%
- Nutricia Baby sales up 9.8%; EBITA margin at 20.1%
- Dumex sales up 23.1%; EBITA margin at 16.5%
- Nutricia Clinical sales up 9.0%; EBITA margin at 26.3%
- Normalised² profit up 33.2% and normalised basic EPS up 16.7% (at reported rates)

CEO Statement

“Numico delivered a strong performance in the first half of 2006 with organic sales growth of 12.4% and margins improving 40 bps to 19.2%. Nutricia Baby Food achieved double-digit organic growth with an improved performance in Western Europe, accompanied by important market share gains in the UK, Italy, Germany, as well as strengthening in the Netherlands. The new immunity claim has been successfully launched in 20 out of 31 countries and has gained positive reception in the medical community. The integration of Dumex is complete and Dumex continued to deliver superior performance during H1, with 26% sales growth at 18% margin. Importantly, the rebuilding of our two factories in Indonesia progressed much faster than anticipated, so H2 impact will be minimal. Nutricia Clinical also posted double-digit growth in H1, despite the impact of the changes in reimbursement in Germany. We have made significant progress with the Alzheimer’s project which now enters the last phase of clinical trials. Based on our strong first half year performance, we are confident that we will be able to reach our sales growth target of 12% - 13% and an EBITA margin of 18.75%.”

Second Quarter		% change		(€ mln)	First Half Year		% change	
2006	2005 ³	comp. ¹	actual		2006	2005 ³	comp. ¹	actual
644	593	11.3	31.2	Sales	1,277	1,156	12.4	36.6
121	104	21.8	30.7	EBITA	239	210	15.2	37.6
73	55	-	33.2	Normalised profit ²	136	98	-	37.8
0.38	0.33	-	16.7	Normalised EPS ²	0.71	0.59	-	20.6
65	54	-	20.4	Profit for the period	112	99	-	14.0
0.34	0.32	-	5.6	Basic EPS (€)	0.59	0.59	-	(0.1)
0.32	0.31	-	5.4	Diluted EPS (€)	0.57	0.57	-	(0.1)

¹ ‘Comparable basis’ is at constant scope of consolidation and constant exchange rates and excluding exceptionals (appendix 5 and 10)

² ‘Normalised’ excludes discontinued businesses, acquisition and integration costs, result divestment after tax and exceptionals (appendix 6)

³ For reconciliation of pro forma Q2 05 sales and EBITA, please refer to appendix 5 and 10

OUTLOOK 2006

Based on the strong performance in the first half of 2006 and the expected performance for the remainder of the year, Numico reconfirms its total sales growth target of 12% - 13% and an EBITA margin of 18.75%. These targets are all based on constant scope of consolidation, constant exchange rates, excluding exceptionals and barring unforeseen circumstances.

UPDATE ON ALZHEIMER'S DISEASE PROJECT

Numico is continuing its development of a proprietary nutritional product for patients with Alzheimer's disease. This is the result of 8 years of research studying nutrition in relation to brain development. The product concept is designed as Food for Special Medical Purposes (FSMP) in Europe and as Medical Food in the US. The product concept is aimed at patients with mild and moderate Alzheimer's disease. It is designed to improve synaptic and neural functions of the brain resulting in a slowdown in the progression of the disease, as determined by improved cognitive function including improved memory performance, thereby enabling patients to maintain a better control of normal daily activities.

Numico has successfully completed its pre-clinical experimental research, in collaboration with Professor Richard Wurtman from M.I.T. in the US and a number of leading scientific experts on Alzheimer's disease in Europe. The outcomes of this research, with animal models, have confirmed improved learning and memory ability and the toxicological evaluations have underpinned that the product is safe.

As a last stage before commercialisation, Numico has now started a clinical trial to test the product in humans. This trial is a randomised, controlled, double-blind, multi-centre, multi-country trial with patients at the mild stage of Alzheimer's. The trial is expected to include over 200 patients in four countries and is expected to be completed by the end of 2007 with the publication of results by mid 2008.

Provided that the results of the trial are positive, Numico is confident that the company will be able to commercialise the product concept for Alzheimer's disease in the course of 2008,.

UPDATE ON EARTHQUAKE IN INDONESIA

The Indonesian earthquake has resulted in €7 mln of lost sales and €3 mln of lost margin in the second quarter of 2006. Numico's baby food operations in Indonesia have been able to recover much faster from the earthquake than initially anticipated with the basic manufacturing plants having returned to full operation in July. Numico expects no further material loss of sales in the third quarter and the total one-off costs are now expected to be less than €10 mln, of which €4 mln has been taken in the second quarter.

FINANCIAL REVIEW *(on a comparable basis⁴)*

First Half Year 2006

(%)	Baby	Dumex	Clinical	Total
Comparable sales growth	10.6	25.7	10.1	12.4
Acquisitions / divestitures	9.5	-	(2.2)	22.6
Currency translation effect	1.6	8.8	1.0	2.2
Impact earthquake	(1.0)	-	-	(0.6)
Reported sales growth	20.7	34.5	8.9	36.6

⁴ 'Comparable basis' is at constant scope of consolidation and constant exchange rates and excl. exceptionals (refer to appendix 5 and 10)

Reported sales increased 36.6% to € 1,277 mln in the first half of 2006. This growth consisted of 12.4% organic growth, driven by 10.6% organic growth for Nutricia Baby, 25.7% for Dumex and 10.1% for Nutricia Clinical. Growth through acquisitions amounted to 22.6% and currency translation effects accounted for 2.2% growth. The earthquake in Indonesia negatively impacted sales growth by 60 bps. Organic sales growth was driven by 8.2% in volume and 4.2% in price/mix.

(€ mln)	Sales			EBITA	EBITA margin	change bps
	H1 06	H1 05 ⁵	change ⁶			
Baby Food	730	666	10.6%	142	19.7%	90
Dumex	186	148	25.7%	33	18.0%	90
Clinical Nutrition	357	326	10.1%	93	26.1%	(120)
Non-allocated	-	-	-	(25)	-	-
Numico continued	1,273	1,140	12.4%	244	19.2%	40

The underlying gross margin improved in the first half 2006 compared to the first half of 2005. This was due to i) favourable product mix and pricing, ii) lower raw material prices – mainly for dairy related products – and iii) cost savings from the various efficiency initiatives.

Numico's overall EBITA margin was 19.2%, an improvement of 40 bps compared to the first half of 2005 despite an increase in A&P and R&D spend of 25% and 21%, respectively.

The effective tax charge and cash tax rate were 29% and 25%, respectively, in line with expectations for the full year. Normalised profit and normalised basic earnings per share amounted to € 136 mln and € 0.71, up 37.8% and 20.6%, respectively.

Second Quarter 2006

(%)	Baby	Dumex	Clinical	Total
Comparable sales growth	9.8	23.1	9.0	11.3
Acquisitions / divestitures	8.1	-	(2.5)	20.5
Currency translation effect	0.2	5.0	(0.1)	0.6
Impact earthquake	(2.0)	-	-	(1.2)
Reported sales growth	16.0	28.1	6.3	31.2

Reported sales increased 31.2% to € 644 mln in the second quarter of 2006. This growth consisted of 11.3% organic growth, 20.5% growth through acquisitions and 0.6% growth as a result of currency translation effects. The earthquake in Indonesia impacted sales growth by 120 bps.

(€ mln)	Sales			EBITA	EBITA margin	change bps
	Q2 06	Q2 05 ⁵	change ⁶			
Baby Food	367	341	9.8%	72	20.1%	240
Dumex	91	74	23.1%	15	16.5%	550
Clinical Nutrition	184	170	9.0%	48	26.3%	(150)
Non-allocated	-	-	-	(13)	-	-
Numico continued	643	585	11.3%	123	19.3%	160

⁵ For reconciliation of pro forma Q1 05 numbers, please refer to appendix 5 and 10

⁶ 'Comparable basis' is at constant scope of consolidation and constant exchange rates and excl. exceptionals (refer to appendix 5 and 10)

The gross margin improved in the second quarter 2006 compared to the first quarter of 2006 as well as the second quarter of 2005, driven by i) favourable product mix, ii) lower raw material prices – mainly in dairy related products – and iii) continued cost savings from the various efficiency initiatives.

Numico's overall EBITA margin was 19.3% or 160 bps higher despite an increase in A&P and R&D spend of 21% and 19%, respectively.

Normalised net profit and normalised earnings per share amounted to €73 mln and €0.38, respectively, up 33.2% and 16.7%.

REVIEW BY ACTIVITY *(on a comparable basis)*⁷

Baby Food

Nutricia Baby sales increased 10.6% to €737 mln in the first half of 2006, excluding €7 mln of lost sales due to the Indonesian earthquake in May. This growth was driven by 6.1% in volume and 4.5% in price/mix. Western Europe grew by 3.5%, supported by strong performances in the UK and Italy and improving performance trends in Germany and the Netherlands. Eastern Europe and the Rest of the World grew by 21% and 20%, respectively, with particularly strong growth in Turkey and Indonesia.

The EBITA margin – excluding €3 mln loss of margin due to the Indonesian earthquake – was 19.7% or 90 bps higher than in the first half of 2005, despite an increase in A&P and R&D spend of 22% and 13%, respectively. Favourable product mix, lower raw material prices and various cost savings initiatives contributed to this margin improvement.

Nutricia Baby sales grew by 9.8% in the second quarter of 2006, excluding €7 mln of lost sales due to the Indonesian earthquake. Sales in Western Europe grew by 4%, most notably driven by continued strong performance in the UK and improvements in Germany. The EBITA margin was 20.1% or 240 bps higher than in the second quarter of 2005, excluding the loss of margin due to the Indonesian earthquake.

Western Europe is well on track to deliver 4 – 5% sales growth in 2006. Market shares in the UK increased 240 bps to 37.8% in the first half of 2006 and Mellin's IMF market share in Italy increased 430 bps in volume-terms in the first half of 2006. Market shares in the Netherlands are approaching levels prior to the price increase and jar recall that took place in the second half of 2005, having gained 300 bps in the last 4 months. In Germany, Numico's IMF market share improved 180 bps to 36.8% in the first half of 2006.

The roll-out of the new immunity Infant Milk Formulae is also progressing very successfully. The new claim "*Naturally Strengthens your Baby's Immune System*" is supported by more than 70 publications and 11 clinical trials. The results have been presented at more than 200 medical congresses and seminars, reaching more than 26,000 healthcare professionals and key opinion leaders in over 20 countries. The new immunity claim has already been introduced in 20 out of 31 countries, and will have been rolled-out in the remaining countries by mid 2007.

Dumex

Sales in Dumex grew by 25.7% to €186 mln in the first half of 2006, supported by all countries and with particularly strong growth in China and Vietnam. Growth was driven by 17.1% in volume and 8.6% in price/mix.

The EBITA margin increased 90 bps to 18.0% despite an increase in A&P spend of 42%. Due to the anticipated marketing initiatives in the second half of the year – primarily relating to the launch of the immunity claim – the level of A&P spend as a percentage of sales is expected to be higher in the second half of 2006.

Sales in Dumex increased by 23.1% in the second quarter of 2006 and the EBITA margin was 16.5% or 550 bps higher than in the second quarter of 2005, despite an increase in A&P spend of 27%. This can mainly be attributed to premiumisation of the product portfolio, more stable fixed costs and phasing of A&P.

⁷ 'Comparable basis' is at constant scope of consolidation and constant exchange rates and excl. exceptionals (refer to appendix 5 and 10)

The integration of Dumex is now complete. The various efficiency initiatives are on track to generate the anticipated annualised cost savings of €5 mln in 2006 and €10 mln in 2007 and beyond. The related acquisition and integration costs amount to €35 mln, of which €23 mln were taken in the first half of 2006. The remaining costs – are expected to be taken in the next 6 months.

Clinical Nutrition

Sales in Clinical Nutrition grew by 10.1% to €357 mln in the first half of 2006. Growth was driven by Southern Europe (+11%) and Rest of the World (+20%) and partly offset by Northern Europe (+6%), adversely impacted by the changes in reimbursement in Germany. As part of the new German reimbursement guidelines, i) general malnutrition products are now reimbursed, ii) disease-specific products require a higher level of clinical evidence and iii) the emphasis is on full diet instead of supplemental solutions. France, Belgium and Brazil delivered particularly strong performances.

The EBITA margin was 26.1% primarily due to an increase in R&D and A&P spend of 33% and 16%, respectively, which explains the 120 bps decrease compared to the first half of 2005.

Sales increased by 9.0% in the second quarter of 2006 and the EBITA margin decreased 150 bps to 26.3% driven by an increase in R&D and A&P spend of 39% and 12%, respectively.

As part of Numico's continuous assessment of its portfolio, the company has decided to evaluate the strategic alternatives for Coeliac, which may entail a sale of the business. Numico's Coeliac business provides a wide range of gluten-free food products to individuals who suffer from gluten intolerance. The Coeliac sector is witnessing strong growth in the retail channel in certain markets where Numico operates, which has driven the need for a strategic evaluation, which is expected to be concluded before year-end. Numico's Coeliac business generates approx. €20 mln of annualised sales with an EBITA margin of over 20%.

OTHER FINANCIAL INFORMATION

Cash Flow

Total trade working capital as a percentage of sales improved 310bps to 10.9% compared to June 2005. This was driven by a further reduction of trade receivables and an ongoing optimisation of trade payables.

Cash generated from operations increased by €97 mln to €228 mln in the first half of 2006, driven by the strong increase in operating profit and supported by the continuous effort to reduce working capital.

Capital expenditure amounted to €70 mln, or 5.5% of sales in the first half of 2006, which is below Numico's full year expectation of 6 – 7%. This is due to the phasing of certain projects that will only commence in the second half of the year, such as investments in selected supply points and several quality related projects. Free cash flow amounted to €120 mln compared to €32 mln in the first half of 2005, excluding the net cash payment related to the EAC Nutrition acquisition of €1,194 mln in the first quarter of 2006.

Net Debt and Finance Costs

Net debt decreased by €64 mln to €1,591 mln in the second quarter of 2006 due to strong free cash flow. Net finance costs amounted to €19 mln in the second quarter of 2006 compared to €28 mln in the first quarter. This is primarily due to positive currency movements in the second quarter compared to the negative trends in the first quarter. More detailed information can be found in appendix 9.

Shareholders' Equity

Shareholders' equity improved by €44 mln to €724 mln in the first half of 2006. This improvement was driven by retained earnings of €112 mln, partly offset by negative currency translation effects on intangible fixed assets primarily related to the Chinese renminbi. An overview of the movements in shareholders' equity can be found in appendix 4.

A live and on-demand audio web cast of the conference call for analysts and investors on Thursday 3 August at 8.30 hrs CET and the related presentation slides will be available on our website (www.numico.com) at 08.00 hrs CET on 3 August 2006.

Appendix 1

Consolidated income statement *(at actual rates)*

Second Quarter			(€ mln)	First Half Year		
2006	2005	% change		2006	2005	% change
644	491	31.2	Sales	1,277	935	36.6
3	6	(53.8)	Other revenues	6	11	(47.8)
647	497	30.1	Total revenues	1,282	945	35.7
(200)	(154)	29.7	Cost of raw materials and consumables	(407)	(284)	43.1
(119)	(108)	10.4	Personnel costs	(259)	(210)	23.4
(80)	(48)	65.7	Advertising and promotion costs	(149)	(89)	66.7
(125)	(91)	37.7	General and administrative costs	(233)	(177)	31.6
(8)	(6)	26.6	Depreciation	(18)	(13)	38.7
(6)	(2)	200.5	Amortisation and impairment fixed assets	(10)	(3)	235.0
1	2	(60.8)	Other income	2	3	(44.6)
110	90	22.2	Operating profit	207	171	21.0
(19)	(12)	50.7	Net finance costs	(46)	(29)	61.7
1	1	-	Share in profit of joint venture	1	1	-
92	79	17.1	Profit before tax	162	144	12.6
(26)	(23)	9.8	Income tax expense	(47)	(43)	9.8
67	55	20.1	Profit from continued operations	115	101	13.7
(1)	-	-	Net loss from discontinued operations	(2)	-	-
65	55	17.9	Profit for the period	113	101	11.6
			<i>Attributable to:</i>			
65	54	20.4	Equity holders	112	99	14.0
0	1	(84.7)	Minority interest	0	3	(82.2)
0.34	0.32	5.6	Basic earnings per share (€)	0.59	0.59	(0.1)
0.32	0.31	5.4	Diluted earnings per share (€)	0.57	0.57	(0.1)

Appendix 2

Consolidated balance sheet

(€ mln)	30 June 2006	31 Dec. 2005
Intangible assets	2,094	767
Property, plant and equipment (PP&E)	383	336
Financial assets	27	26
Deferred income tax assets	359	362
Derivative financial instruments	-	9
Non-current assets	2,863	1,500
Inventories	269	194
Trade receivables	302	285
Other receivables	103	78
Cash and cash equivalents	285	1,457
Current assets	959	2,014
Non-current assets classified as held for sale	26	22
Total assets	3,848	3,536
Capital and reserves attributable to equity holders	724	680
Minority interest	4	2
Total equity	728	682
Borrowings	1,695	1,913
Employee benefits	111	110
Provisions	7	7
Deferred income tax liabilities	412	181
Derivative financial instruments	7	13
Other financial liabilities	89	50
Non-current liabilities	2,321	2,274
Trade payables	303	254
Other payables	245	168
Current income tax liabilities	87	73
Borrowings	153	62
Provisions	10	22
Derivative financial instruments	1	1
Current liabilities	799	580
Total equity and liabilities	3,848	3,536

Intangible assets

The increase in intangible assets of € 1,327 mln can mainly be explained by the brands and goodwill related to the acquisition of EAC Nutrition of € 859 mln and € 513 mln, respectively, and negative exchange rate differences.

Property, plant and equipment (PP&E)

The increase of € 47 mln is mainly related to the acquisition of EAC Nutrition on 2 January 2006.

Deferred income tax liabilities

The increase in deferred income tax liabilities of € 231 mln mainly results from the recognition of the Dumex brand name that was acquired on 2 January 2006 as part of the acquisition of EAC Nutrition.

Appendix 3

Consolidated cash flow statement

(€ mln)	First Half Year	
	2006	2005
Operating profit	207	171
<u>Adjustments:</u>		
Depreciation	22	14
Amortisation and impairment	10	3
Movement in provisions	(12)	(14)
Net change in trade working capital	11	(23)
Net change in non-trade working capital	(21)	(20)
Other	11	-
	21	(40)
Cash generated from operations	228	131
Interest received	7	8
Interest paid	(41)	(37)
Income tax paid	(26)	(39)
	(60)	(68)
Cash flow from operating activities	168	63
<u>Investing activities</u>		
Proceeds of sale of PP&E	12	8
Capital expenditures	(70)	(48)
Acquisition EAC Nutrition / Mellin	(1,194)	(198)
Proceeds of divestments	10	3
Loan repayments received from third parties	-	6
Cash flow from investing activities	(1,242)	(229)
<u>Financing activities</u>		
(Redemption)/Use of credit facility	(190)	405
Changes in ST loans and bank overdrafts	11	-
Issued commercial paper and senior notes	71	340
Repurchase of convertible bonds	-	(627)
Repurchase of shares by subsidiaries	-	(6)
Issued shares	10	3
Dividends paid	(14)	-
Minority interest	-	(2)
Cash flow from financing activities	(112)	113
Exchange rate differences	-	-
Change in cash (equivalents) and bank overdrafts	(1,186)	(53)
Cash (equivalents) and bank overdrafts 1 January	1,426	220
Bank overdrafts 1 January	(31)	
Cash (equivalents) and bank overdrafts 30 June	240	167
Bank overdrafts 30 June	(45)	
Free cash flow*	120	32

* Cash flow from operating activities minus cash flow from investing activities (excluding net cash payment of € 1,194 mln related to acquisition EAC Nutrition and € 198 mln related to the acquisition of Mellin).

Appendix 4

Consolidated statement of recognised income and expense

Q2 06	Q2 05	(€ mln)	HY 06	HY 05
2	(8)	Cash flow hedges fair value gains (losses) net of tax	9	(9)
(85)	8	Exchange rate differences	(89)	11
83	0	Net expense charged directly against equity	(80)	2
65	55	Profit for the period	113	101
(18)	55	Total recognised income for the period	33	103
		Attributable to:		
(19)	53	Equity holders	32	100
1	2	Minority interest	1	3

Movements in shareholders' equity

(€ mln)	
Shareholders' equity at 31 December 2005	680
Profit for the period	112
Net expense charged directly against equity	(80)
Dividend paid	(14)
Issued share capital – stock options	10
Costs of stock options	15
Other movements	1
Shareholders' equity at 30 June 2006	724

The dividend related to 2005 of €0.15 per ordinary share has been paid out in cash (€14 mln) and a corresponding value in stock dividend.

Shareholders' equity increased €10 mln due to issued share capital resulting from exercised personnel stock options and convertible personnel debenture loans in the first half year of 2006.

Number of shares outstanding

Q2 06	Q2 05	(mln)	HY 06	HY 05
191.04	173.22	At period end	191.04	173.22
190.51	166.94	Period average	190.32	166.64
211.33	186.70	Diluted	211.28	186.26

The increase of the number of ordinary shares outstanding compared to a year ago can mainly be explained by the issuance of 16.6 mln shares related to the acquisition of EAC Nutrition in the fourth quarter of 2005.

The difference (20.3 mln shares) between the number of ordinary shares outstanding and the diluted number of shares used to calculate diluted earnings per share can be explained by the potential dilutive effect of 16.4 mln shares related to the convertible debenture loan 2003 and the dilutive effect of performance shares and stock options.

Appendix 5

Reconciliation of pro forma sales and EBITA for Q2 05

The tables below provide a reconciliation of the pro forma sales and EBITA performance per activity in Q2 05 used – as a ‘comparable basis’ – to assess the growth performance excluding consolidation and currency translation effects in Q2 06. The reconciliation adjusts the Q2 05 performance for currency effects and includes the pro forma performance of Mellin in Baby Food and the pro forma performance of continued businesses of EAC Nutrition in Dumex.

Reconciliation of sales in Q2 05 to a ‘comparable basis’

(€ mln)	Baby	Dumex	Clinical	Total
Sales reported in Q2 05	317	-	174	491
Pro forma sales acquisitions (Mellin, Dumex)	29	71	-	101
Businesses to be divested	(6)	-	(3)	(9)
Currency translation effect	1	3	(0)	3
Sales Q2 05 on a comparable basis	341	74	170	585

Reconciliation of EBITA in Q2 05 to a ‘comparable basis’

(€ mln)	Baby	Dumex	Clinical	Non-alloc	Total
EBITA reported in Q2 05	56	-	48	(11)	92
Pro forma sales acquisitions (Mellin, Dumex)	5	8	-	-	13
Businesses to be divested	(1)	-	(0)	-	(1)
Currency translation effect	1	0	0	(0)	1
EBITA Q2 05 on a comparable basis	60	8	48	(12)	105

Appendix 6

Reconciliation of EBITA and operating profit

Q2 06	Q2 05	(€ mln)	HY 06	HY 05
123	105	EBITA on a comparable basis	244	215
-	(13)	Pro forma contribution of acquisitions Mellin and Dumex in Q2 05	-	(36)
(2)	(1)	EBITA of businesses to be divested	(5)	(5)
-	2	Currency translation effect	-	(1)
121	93	EBITA as reported	239	174
(3)	(2)	Exceptionals	(2)	(2)
-	2	Result divestments	-	3
(5)	0	Acquisition and integration costs	(23)	0
(3)	(2)	Amortisation and impairment	(7)	(3)
110	90	Operating profit as reported	207	171

Reconciliation of profit and normalised profit

Q2 06	Q205	(€ mln)	HY 06	HY 05
65	54	Profit attributable to equity holders	112	99
1	-	Net loss from discontinued operations	2	-
-	(1)	Result divestments (net of tax)	-	(2)
5	-	Acquisition and integration costs (net of tax)	20	-
2	2	Exceptionals (net of tax)	1	2
73	55	Normalised profit attributable to equity holders	136	98

Appendix 7

Information by activity – First half 2006

The sales and EBITA (margin) numbers for the first half of 2005 are on a pro forma basis. Please refer to appendix 5 for a detailed reconciliation. The comparable growth numbers for Baby Food are adjusted for the loss of sales (€7 mln) and margin loss (€3 mln) due to the earthquake in Indonesia. The comparable growth numbers for Clinical Nutrition are adjusted for the sales and margin of the Coeliac business (please refer to page 5 of this press release).

SALES (€ mln)	First Half Year		% change	
	2006	2005	comparable	actual
	Baby Food	730	666	10.6
Dumex	186	148	25.7	34.5
Clinical Nutrition	357	326	10.1*	10.6
Sales continued business	1,273	1,140	12.4*	13.9
Businesses to be divested	4	16		
Total Sales	1,277	1,156	11.1	12.8

EBITA (€ mln)	First Half Year		% change	
	2006	2005	comparable	actual
	Baby Food	142	125	16.3
Dumex	33	25	32.0	43.0
Clinical Nutrition	93	89	5.6*	4.9
Non-allocated	(25)	(24)	-	-
EBITA continued business	244	215	15.2*	15.2
Businesses to be divested	(5)	(5)	-	-
Total EBITA	239	210	15.2	16.6

EBITA margin (%)	First Half Year		change in bps	
	2006	2005	comparable	actual
	Baby Food	19.7	18.8	90
Dumex	18.0	17.1	90	110
Clinical Nutrition	26.1*	27.3	(120)*	(140)
EBITA margin continued business	19.2*	18.8	40*	30
Total EBITA as a % of sales	18.9	18.2	70	60

* Numbers exclude the performance of the Coeliac business

Appendix 8

Information by activity – Second quarter 2006

The sales and EBITA (margin) numbers for Q2 05 are on a pro forma basis. Please refer to appendix 5 for a detailed reconciliation. The comparable growth numbers for Baby Food are adjusted for the loss of sales (€7 mln) and margin loss (€3 mln) due to the earthquake in Indonesia. The comparable growth numbers for Clinical Nutrition are adjusted for the sales and margin of the Coeliac business (please refer to page 5 of this press release).

SALES (€ mln)	Second Quarter		% change	
	2006	2005	comparable	actual
	Baby Food	367	341	9.8
Dumex	91	74	23.1	28.1
Clinical Nutrition	184	170	9.0*	8.2
Sales continued business	643	585	11.3*	10.5
Businesses to be divested	1	8	-	-
Total Sales	644	593	9.7	9.3

EBITA (€ mln)	Second Quarter		% change	
	2006	2005	comparable	actual
	Baby Food	72	60	24.7
Dumex	15	8	84.9	87.6
Clinical Nutrition	48	48	3.0*	1.0
Non-allocated	(13)	(12)	-	-
EBITA continued business	123	105	21.8*	17.1
Businesses to be divested	(2)	(1)	-	-
Total EBITA	121	104	20.3	19.1

EBITA margin (€ mln)	Second Quarter		change in bps	
	2006	2005	comparable	actual
	Baby Food	20.1	17.7	240
Dumex	16.5	11.0	550	520
Clinical Nutrition	26.3*	27.8	(150)*	(180)
EBITA margin continued business	19.3*	17.7	160*	100
Total EBITA as a % of sales	19.1	17.5	160	150

* Numbers exclude the performance of the Coeliac business

Appendix 9

Net debt

(€ mln)	30 June 2006	31 Dec. 2005
Convertible debenture loan 2003	345	345
Other convertibles	7	7
Convertible loans	352	352
Bank loan	900	1,090
Senior notes	487	525
Other loans	113	31
Cash and cash equivalents	(240)	(1,426)
Sub total net debt	1,611	572
Financial instruments and cross currency swaps	(20)	(57)
Total net debt	1,591	515

Net finance costs

(€ mln)	2006		2005		
	Q2	Q1	Q4	Q3	Q2
Interest expenses	(24)	(24)	(17)	(18)	(17)
Interest income	5	4	5	4	6
Net interest expenses	(19)	(20)	(12)	(14)	(11)
Other	(1)	0	1	-	-
Sub-total financial income and expenses	(20)	(20)	(11)	(14)	(11)
Fin. instruments and currency translation effects	1	(7)	(5)	-	(3)
Total net finance costs	(19)	(28)	(16)	(14)	(14)

Appendix 10

GENERAL INFORMATION

This interim financial report has been prepared in accordance with IFRS. The applied accounting policies are consistent with the accounting policies used to prepare the annual financial statements for the year ended 31 December 2005. New standards, amendments and interpretations mandatory for 2006 have been adopted. Out of the new standards, IFRIC 4 is the only standard with an effect on the reported figures.

It is to be noted that all numbers in this report are unaudited and that performance comparisons versus the same period in the preceding year in 'Financial Review' and 'Review by Activity' are made on a 'comparable basis' to facilitate like-for-like comparability. The 'comparable basis' is based on i) constant exchange rates, ii) constant scope of consolidation and iii) excluding exceptionals. Constant consolidation implies that businesses that will be divested are excluded and that the second quarter and first half year 2005 numbers incorporate the pro forma performance of Mellin (consolidated as of 23 June 2005) and Dumex (consolidated as of 2 January 2006). An overview of the adjustments is provided for in appendix 5. It is to be noted that totals might deviate from the sum of the individual inputs due to rounding.

Numico acquired 100% of the shares of EAC Nutrition – for a net amount of €1,194 mln in cash – on 2 January 2006. The company intends to focus the activities of EAC Nutrition on profitable growth in these core markets and has therefore closed down the Dumex activities in the Philippines and sold respectively the Hangzhou Future cereals plant in China and the Dumex activities in India. Numico has concluded the Purchase Price Allocation (PPA) for Dumex which is incorporated in the consolidated balance sheet at 30 June 2006. Some minor deviations may occur in the second half of the year due to the final settlement of the purchase price. This will have a limited effect on cash and goodwill. Details of the net assets acquired and goodwill are as follows:

<i>(€ mln)</i>	
Purchase consideration	1,194
Costs / deferred payment directly attributable to the acquisition	17
Total purchase consideration	1,211
Fair value of net assets acquired	698
Goodwill	513

Goodwill amounts to €513 mln and is attributable to the high profitability of the acquired business and the expected synergies for the Dumex group. The brand value amounts to €859 mln, reflecting the expected future cash flows arising from the acquired Dumex brand. This brand is considered to have an indefinite life as it is a very strong and well known brand in the Asian market and has a proven track record. The company has no intention of abandoning the Dumex name.

<i>(€ mln)</i>	Fair Value	Dumex carrying amount
PP&E	46	70
Goodwill	513	16
Brands	859	-
Other intangible assets	6	6
Financial assets	4	4
Assets held for sale	12	-
Deferred income tax asset	2	2
Inventories	40	39
Receivables	48	50
Employee benefits	(1)	(1)
Deferred income tax liabilities	(243)	(2)
Payables	(75)	(77)
Net assets acquired	1,211	107

WARNING ABOUT FORWARD-LOOKING STATEMENTS

Some statements in this document are forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. These forward-looking statements involve known and unknown risks, uncertainties and other factors that are outside of our control and impossible to predict and may cause actual results to differ materially from any future results expressed or implied.

These forward-looking statements are based on current expectations, estimates, forecasts and projections and our beliefs and assumptions about future events. Forward-looking statements include, without limitation, statements concerning Numico's results or financial position and the other factors discussed in the company's annual report. An overview of the most important financial factors that may affect Numico's results are provided in the company's most recent Annual Report.

Given these uncertainties, no assurance can be given as to Numico's future results or financial position. You are cautioned not to put undue reliance on these forward-looking statements, which only speak as of the date of this document and are neither predictions nor guarantees of future events or circumstances. Numico does not undertake any obligation to release publicly any revisions to these forward-looking statements to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.